[{"orgOrder":0,"company":"EffRx Pharmaceuticals","sponsor":"Abiogen Pharma S.p.A","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Alendronate Sodium","moa":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"EffRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet, Effervescent","sponsorNew":"EffRx Pharmaceuticals \/ Abiogen Pharma S.p.A","highestDevelopmentStatusID":"12","companyTruncated":"EffRx Pharmaceuticals \/ Abiogen Pharma S.p.A"},{"orgOrder":0,"company":"EffRx Pharmaceuticals","sponsor":"Radius Health","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Alendronate Sodium","moa":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"EffRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet, Effervescent","sponsorNew":"EffRx Pharmaceuticals \/ Radius Health","highestDevelopmentStatusID":"12","companyTruncated":"EffRx Pharmaceuticals \/ Radius Health"}]

Find Clinical Drug Pipeline Developments & Deals for Alendronate Sodium

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Under the agreement, EffRx will grant Radius an exclusive, royalty bearing license to Binosto (alendronate sodium), an effervescent tablet for oral solution indicated for osteoporosis in postmenopausal women and to increase bone mass in men with osteopor...

                          Brand Name : Binosto

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 19, 2023

                          Lead Product(s) : Alendronate Sodium

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved

                          Sponsor : Radius Health

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          02

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Through the acquisition, Abiogen gets Effrx's Binosto (alendronate sodium), an effervescent tablet for the treatment of osteoporosis. It will allow Abiogen to continue developing on Effrx's bisphosphonates family of molecules that in the area of ​​os...

                          Brand Name : Binosto

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 29, 2023

                          Lead Product(s) : Alendronate Sodium

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved

                          Sponsor : Abiogen Pharma S.p.A

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank